Cochlear Stock

Cochlear FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cochlear (COH.AX) as of Sep 8, 2026 is 34.71 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 83.80 % — a change of -58.58% (lower).

FCF Conversion

34.71 %

YoY

-58.58%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cochlear is 2026 34.71 % . FCF Conversion Rate (FCF/EBITDA) of Cochlear was 2025 83.80 % . It decreases by -58.58% lower compared to the previous year.

The Cochlear FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
84.78 AUD
Jan 1, 2019
65.56 AUD
Jan 1, 2020
120.98 AUD
Jan 1, 2021
60.86 AUD
Jan 1, 2022
103.53 AUD
Jan 1, 2023
88.66 AUD
Jan 1, 2024
83.80 AUD
Jan 1, 2025
34.71 AUD
The Cochlear FCF Conversion history
YEARFCF ConversionYoY
34.71 %-58.58%
83.80 %-5.48%
88.66 %-14.37%
103.53 %+70.12%
60.86 %-49.70%
120.98 %+84.54%
65.56 %-22.68%
84.78 %+0.47%
84.39 %+8.04%
78.11 %-28.93%
109.90 %+29.53%
84.85 %
Access this data via the Eulerpool API

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

FCF Conversion Rate (FCF/EBITDA) of Cochlear is 34.71 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Cochlear changed from 83.80 % to 34.71 %, representing a -58.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cochlear since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cochlear with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Cochlear

All Key Metrics — Cochlear